HC Wainwright Rates Elicio Therapeutics (ELTX) buy

HC Wainwright maintains its buy rating for Elicio Therapeutics with a $23 price target, a 388.32% upside from the current price.

By EarningsIQ Research Desk · Published Jun 15, 2026, 9:01 AM EDT · Updated Jun 18, 2026, 1:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

HC Wainwright rated Elicio Therapeutics, Inc. ($ELTX) "buy" with a $23 price target on June 15, 2026.

Since the rating, $ELTX is up 1.5% after 1 week, down 25.5% after 1 month and down 61.8% to date (from the $4.08 close on Jun 15, 2026).

ELTX Elicio Therapeutics, Inc.

$1.56 -80.62% year to date

Daily close · Oct 16, 2026

Key Points

HC Wainwright reiterated its buy rating on Elicio Therapeutics, maintaining a $23 price target as of June 15, 2026.
HC Wainwright's $23 price target implies 388.32% upside from Elicio Therapeutics, Inc.'s ($ELTX) current $4.71 share price.
Elicio Therapeutics, trading at $14.85, has a market cap of $283 million and a 52-week range between $7.37 and $16.00.
Vanguard Capital Management added 518,638 shares of Elicio, while Balyasny Asset Management increased its stake by 106,052 shares.

Get $ELTX trade alerts by text

We text you when insiders, Congress or big funds trade $ELTX. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Elicio Therapeutics, Inc. alert may contain errors. Disclosures

HC Wainwright & Co. reiterated its buy rating for Elicio Therapeutics, Inc. (NasdaqCM: ELTX) on June 15, 2026, maintaining a price target of $23. This reflects confidence in the biotechnology firm's prospects, as shares currently trade at $14.85.

Other Institutional Activity in Elicio Therapeutics

Notable institutional activity includes Vanguard Capital Management, which added 518,638 shares, bringing its total to 518,638 shares valued at approximately $5.54 million. Balyasny Asset Management increased its holdings by 106,052 shares, resulting in a total of 244,814 shares worth about $2.62 million. Meanwhile, Geode Capital Management modestly grew its stake by 2,646 shares, ending with 135,164 shares valued at $1.45 million. Renaissance Technologies significantly boosted its position by 93,520 shares, totaling 121,631 shares valued at $1.3 million.

Elicio Therapeutics, Inc. Stock Up 149.2%

Shares of Elicio Therapeutics are trading near $14.85. The company has a market capitalization of approximately $283 million. Although it is not yet profitable, its forward P/E ratio is not meaningful. The stock's 52-week range is between $7.37 and $16.00, with a 50-day moving average of $11.37 and a 200-day moving average of $10.07. Elicio has a current ratio of 2.24 and a quick ratio of 2.07, reflecting solid liquidity.

12-month forecast

$ELTX price target

Elicio Therapeutics, Inc. daily closes and this analyst's $23 target. Not advice.

Insider Buying and Selling at Elicio Therapeutics, Inc.

On February 2, 2026, several executives at Elicio Therapeutics made notable stock purchases. CEO Robert Connelly acquired 147,200 shares, while Chief Scientific Officer Peter Demuth and Chief Strategy and Financial Officer Preetam Shah bought 41,600 and 47,900 shares, respectively. Executive Vice President Christopher Haqq also purchased 25,400 shares. These transactions were not part of a pre-planned trading program.

Analysts Set New Price Targets

On June 15, 2026, HC Wainwright maintained its buy rating for Elicio Therapeutics with a $23 price target. Earlier, on June 10, 2026, B. Riley Securities initiated coverage with a buy rating and a $27 target. Ladenburg Thalmann also initiated coverage on April 15, 2026, with a buy rating and a $20 target. The consensus among analysts is a strong buy, with an average target price of $20.67 based on three opinions.

About Elicio Therapeutics

Elicio Therapeutics, Inc., based in Boston, Massachusetts, is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment. Its lead product, ELI-002, is a vaccine targeting specific cancer mutations, currently in Phase II trials. The company is also working on ELI-007 and ELI-008, targeting other cancer mutations. Elicio is led by CEO Robert T. Connelly and employs 33 people.

Bottom Line

HC Wainwright's reiterated buy rating and $23 target price signal continued confidence in Elicio Therapeutics' potential. Investors track such ratings to gauge market sentiment, though these are backward-looking and may not reflect current conditions. With its focus on innovative cancer treatments, Elicio remains a company to watch in the biotechnology sector.